iX Biopharm Ltd ("iX" or the "Company") is issuing 65.5m shares at $0.46 each. The public tranche is for 1m with the balance through placement. I will just do a high level "copy and paste" analysis on the Company. Before I start, I want to declare that I know nothing about this sector. You may want to refer to my post on QT Vascular on how I "validated" the medical technology then. Having said that and looking through the prospectus, this Company is probably too high risk for me and to be able to list under current bear market conditions at such high valuation is a really "astonishing" for me. The Company is a drug development company with 3 drugs under development. It has its roots in Australia. Financial Highlights As you can see, this is a loss making company and its products are ......